Papp L Roy & Associates Increases Position in C.R. Bard, Inc. (BCR)

Papp L Roy & Associates increased its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 0.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,845 shares of the medical instruments supplier’s stock after buying an additional 50 shares during the period. C.R. Bard accounts for about 1.7% of Papp L Roy & Associates’ investment portfolio, making the stock its 17th largest position. Papp L Roy & Associates’ holdings in C.R. Bard were worth $7,666,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in BCR. Haverford Trust Co. raised its stake in shares of C.R. Bard by 0.3% in the fourth quarter. Haverford Trust Co. now owns 4,012 shares of the medical instruments supplier’s stock worth $901,000 after buying an additional 11 shares during the last quarter. Keybank National Association OH raised its stake in shares of C.R. Bard by 0.3% in the fourth quarter. Keybank National Association OH now owns 4,353 shares of the medical instruments supplier’s stock worth $978,000 after buying an additional 13 shares during the last quarter. ETRADE Capital Management LLC raised its stake in shares of C.R. Bard by 1.7% in the third quarter. ETRADE Capital Management LLC now owns 1,054 shares of the medical instruments supplier’s stock worth $236,000 after buying an additional 18 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of C.R. Bard by 0.5% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,215 shares of the medical instruments supplier’s stock worth $947,000 after buying an additional 20 shares during the last quarter. Finally, Burns J W & Co. Inc. NY raised its stake in shares of C.R. Bard by 1.3% in the first quarter. Burns J W & Co. Inc. NY now owns 1,581 shares of the medical instruments supplier’s stock worth $393,000 after buying an additional 21 shares during the last quarter. Institutional investors own 88.04% of the company’s stock.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

C.R. Bard, Inc. (BCR) traded up 0.21% during trading on Tuesday, reaching $315.84. 211,621 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $309.70 and a 200 day moving average price of $258.71. The firm has a market capitalization of $22.87 billion, a price-to-earnings ratio of 40.20 and a beta of 0.64. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $316.22.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.22. The firm had revenue of $938.80 million during the quarter, compared to the consensus estimate of $916.15 million. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The firm’s revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the business earned $2.34 EPS. Equities research analysts forecast that C.R. Bard, Inc. will post $11.78 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 4th. Stockholders of record on Monday, July 24th will be paid a $0.26 dividend. The ex-dividend date is Thursday, July 20th. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. C.R. Bard’s payout ratio is 13.21%.

TRADEMARK VIOLATION NOTICE: This report was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.thestockobserver.com/2017/06/20/papp-l-roy-associates-has-7-67-million-stake-in-c-r-bard-inc-bcr-updated.html.

BCR has been the subject of several recent research reports. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 price target for the company in a report on Thursday, May 11th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $237.00 price objective on shares of C.R. Bard in a research report on Monday, March 27th. Morgan Stanley downgraded shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research report on Monday, April 24th. BMO Capital Markets reaffirmed a “buy” rating and issued a $255.00 price objective on shares of C.R. Bard in a research report on Tuesday, April 11th. Finally, Raymond James Financial, Inc. downgraded shares of C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a research report on Wednesday, April 26th. Twelve analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. C.R. Bard has a consensus rating of “Hold” and an average price target of $265.62.

In other news, VP Frank Lupisella, Jr. sold 3,622 shares of the stock in a transaction on Monday, April 24th. The stock was sold at an average price of $304.00, for a total value of $1,101,088.00. Following the completion of the transaction, the vice president now owns 10,139 shares of the company’s stock, valued at $3,082,256. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.80% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply